Nocion Therapeutics Raises $62 Million for Innovative Treatment Development

March 7, 2024, 2:30 pm
Nocion Therapeutics
Nocion Therapeutics
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Founded date: 2018
Total raised: $89M
WATERTOWN, MA - Nocion Therapeutics, a cutting-edge biopharmaceutical company, secures $62 million in Series B funding to propel their groundbreaking treatment development. Nocion's focus lies in creating small molecule sodium channel blockers, known as nocions, to target and silence activated nociceptors for conditions like cough, itch, and pain. The funds will drive the evaluation of their lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study for Chronic Cough patients.